1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38


End-of-day quote Shanghai Stock Exchange  -  05-12
45.26 CNY   +0.49%
05/13Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Treatment
05/11Chinese Shares Post Modest Gains; Gotion Jumps 4.5% on Argentina Deal
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

01/11/2022 | 03:31am EDT

SHANGHAI and NEW YORK, Jan. 11, 2022 /CNW/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.

This strategic collaboration includes an AI-driven drug discovery research and development (R&D) collaboration on four biological targets, as well as the co-development of Insilico's QPCTL program. Insilico will receive a total upfront payment of $13 million for the R&D collaboration projects and the co-development of the QPCTL program, potential milestone-based payments, and share commercialization profits from the QPCTL program. In addition, Fosun Pharma will make an equity investment in Insilico.

"We are pleased to enter into strategic collaboration with Insilico. Fosun Pharma is committed to promoting innovative R&D, and is oriented towards fulfilling unmet clinical needs and improving products' accessibility. We look forward to working with Insilico to leverage the technological and clinical development strengths of both companies, jointly improving the efficiency of innovative drug R&D, and benefiting more patients worldwide," said Yifang Wu, Chairman and CEO of Fosun Pharma.

The collaboration aims to combine Insilico's end-to-end AI-driven drug discovery platforms and Fosun Pharma's clinical development and commercial expertise to discover and develop a portfolio of novel therapeutics. Pursuant to the collaboration agreement, Insilico will take responsibility for delivering a preclinical candidate for the QPCTL program and advancing it to IND stage, after which, Fosun Pharma will then conduct human clinical studies and co-develop the candidate globally. In parallel, Fosun Pharma's R&D team will nominate four therapeutic targets to be assessed by Insilico's AI platform and R&D team, who are responsible of advancing drug candidates to IND stage. 

As part of the collaboration, Fosun Pharma will secure access to Insilico's PandaOmics and Chemistry42 platforms in order to advance Fosun Pharma's internal AI-powered discovery and development efforts. 

"In partnering with Fosun Pharma, a leading pharmaceutical company, we begin a new era of AI-powered end-to-end drug discovery and development as human-machine collaboration becoming the new normal in precision drug discovery and development. We previously demonstrated that AI can be used to discover novel targets and generate novel molecules that can be tested in humans in record time. Now, we are partnering with one of the leading scientific teams in the pharmaceutical industry to take this technology to the next level for the benefit of patients worldwide", said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. 

About Fosun Pharma 
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading innovation-driven international healthcare group in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma's business extends to pharmaceutical distribution and retail.

Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, "4 hypers" (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.

Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.

For more information, please visit: www.fosunpharma.com.

Fosun Pharma Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of the Company's business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of the Company's industry and the future development of the general economy of the Company's key markets and any statements preceded by, followed by or that include words and expressions such as "expect", "seek", "believe", "plan", "intend", "estimate", "project", "anticipate", "may", "will", "would" and "could" or similar words or statements, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, the Company does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to the Company's intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.

About Insilico Medicine 
Insilico Medicine, an end-to-end AI-driven drug discovery and development company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. Insilico Medicine has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases and aging-related diseases. For more information, visit www.insilico.com.

For further information, images, or interviews, please contact media@insilicomedicine.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html

SOURCE Insilico Medicine

© Canada Newswire, source Canada Newswire English

05/13Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Tre..
05/11Chinese Shares Post Modest Gains; Gotion Jumps 4.5% on Argentina Deal
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
05/05Hangzhou Calibra Diagnostics Co., Ltd. announced that it has received CNY 220 million i..
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notification letter and request form to non-registered sha..
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the 2022 first m..
04/28SHANGHAI FOSUN PHARMACEUTICAL : Form of proxy for holders of h shares for the annual gener..
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notice of 2022 first h shareholders class meeting (h share..
04/28SHANGHAI FOSUN PHARMACEUTICAL : Notice of annual general meeting (h shares)
04/28SHANGHAI FOSUN PHARMACEUTICAL : Circular - annual general meeting; proposed issuance of co..
More news
More recommendations
Sales 2022 43 494 M 6 407 M 6 407 M
Net income 2022 5 095 M 751 M 751 M
Net Debt 2022 16 460 M 2 425 M 2 425 M
P/E ratio 2022 23,1x
Yield 2022 1,24%
Capitalization 107 B 15 771 M 15 771 M
EV / Sales 2022 2,84x
EV / Sales 2023 2,50x
Nbr of Employees 36 279
Free-Float 58,6%
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 45,26 CNY
Average target price 55,27 CNY
Spread / Average Target 22,1%
EPS Revisions
Managers and Directors
Yi Fang Wu Chairman & Chief Executive Officer
Yu Qing Chen Co-President
Ke Xin Wang Vice Chairman & Co-President
Dong Ming Li Co-President
De Yong Wen Senior Vice President